Central Nervous System Agents
This graph shows the total number of publications written about "Central Nervous System Agents" by people in the URMC Research Network by year, and whether "Central Nervous System Agents" was a major or minor topic of these publication.
Below are the most recent publications written about "Central Nervous System Agents" by people in Profiles.
-
Wang SJ, Hung HM, O'Neill R. Adaptive design clinical trials and trial logistics models in CNS drug development. Eur Neuropsychopharmacol. 2011 Feb; 21(2):159-66.
-
Cory-Slechta DA, Virgolini MB, Rossi-George A, Weston D, Thiruchelvam M. Experimental manipulations blunt time-induced changes in brain monoamine levels and completely reverse stress, but not Pb+/-stress-related modifications to these trajectories. Behav Brain Res. 2009 Dec 14; 205(1):76-87.
-
Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008 Nov 25; 71(22):1770-5.
-
Goldman SA. Disease targets and strategies for the therapeutic modulation of endogenous neural stem and progenitor cells. Clin Pharmacol Ther. 2007 Oct; 82(4):453-60.
-
Kellogg CK, Guillet R. Developmental effects of neuroactive drugs. Prog Clin Biol Res. 1988; 281:265-77.
